Luciole Pharmaceuticals

Executive Summary

Luciole Pharmaceuticals is a Boston-based virtual biotechnology startup pioneering small molecule activators of the OGG1 enzyme to repair oxidative damage in mitochondrial DNA (mtDNA). The company's platform targets the upstream link between mtDNA damage, inflammation, and mitochondrial dysfunction, offering a novel therapeutic approach for age-related diseases, with an initial focus on neurodegenerative conditions. Founded in 2020, Luciole is at a preclinical stage, leveraging its unique OGG1 activation mechanism to potentially slow or reverse disease progression by restoring mitochondrial health. The company's virtual model allows capital-efficient operations, but it remains early-stage with no disclosed funding or pipeline visibility, limiting near-term valuation catalysts.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing60% success
• Q2 2027Lead Candidate Selection50% success
• Q1 2027Preclinical Proof-of-Concept Data Release45% success